Table 2.
Univariate analysis of overall survival and progression-free survival rates
| Variables | OS | DFS | |||||
|---|---|---|---|---|---|---|---|
| One-year (%) | Two-year (%) | p | One-year (%) | Two-year (%) | p | ||
| Age | < 65 years (n = 10) | 80 | 58 | 0.9737 | 50 | 50 | 0.7912 |
| ≥ 65 years (n = 11) | 82 | 64 | 55 | 45 | |||
| Sex | male (n = 8) | 75 | 63 | 0.7274 | 50 | 38 | 0.4961 |
| female (n = 13) | 85 | 59 | 54 | 54 | |||
| Pittsburgh staging | T3 (n = 10) | 80 | 70 | 0.4986 | 70 | 60 | 0.2486 |
| T4 (n = 11) | 82 | 55 | 36 | 36 | |||
| Neurological findings before treatment | yes (n = 8) | 88 | 63 | 0.8889 | 50 | 50 | 0.8762 |
| no (n = 13) | 77 | 61 | 54 | 46 | |||
| Surgery | yes (n = 13) | 85 | 61 | 0.9332 | 46 | 46 | 0.8117 |
| no (n = 8) | 75 | 63 | 63 | 50 | |||
| Systemic therapy | yes (n = 9) | 78 | 65 | 0.8968 | 44 | 44 | 0.8652 |
| no (n = 12) | 83 | 58 | 58 | 50 | |||
| Radiation dose (Gy) | < 66 Gy (n = 4) | 75 | - | 0.0747 | 25 | - | 0.3079 |
| ≥ 66 Gy (n = 17) | 82 | 70 | 59 | 53 | |||
| Irradiated field | local (n = 12) | 83 | 58 | 0.1593 | 42 | 33 | 0.1209 |
| local + prophylactic (n = 9) | 78 | 67 | 67 | 67 | |||
| NLR | < 3.95 (n = 16) | 94 | 74 | 0.0365 | 63 | 56 | 0.1603 |
| ≥ 3.95 (n = 5) | 40 | 20 | 20 | 20 | |||
| CAR | < 0.31 (n = 16) | 88 | 74 | 0.0019 | 69 | 63 | 0.0025 |
| ≥ 0.31 (n = 5) | 60 | 20 | 0 | 0 | |||
| PLR | < 216 (n = 12) | 92 | 74 | 0.129 | 67 | 58 | 0.2853 |
| ≥ 216 (n = 9) | 67 | 44 | 33 | 33 | |||
| AGR | < 1.34 (n = 11) | 73 | 44 | 0.1993 | 36 | 36 | 0.3666 |
| ≥ 1.34 (n = 10) | 90 | 80 | 70 | 60 | |||
OS; overall survival, PFS; progression-free survival, NLR; neutrophil-to-lymphocyte ratio, CAR; C-reactive protein-to-albumin ratio, PLR; platelet-to-lymphocyte ratio, AGR; albumin-to-globulin ratio.